SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is experiencing significant volatility as investors weigh the impact of rising oil prices and geopolitical tensions against persistent rumors of supply shortages and COMEX inventory fluctuations. While some in the community view this pullback as a potential buying opportunity amidst long-term industrial demand, others are wary of bearish technical signals and the influence of institutional short sellers on price discovery.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as investors and the community digest the official unveiling of the R2 midsize SUV, which features multiple trim levels and a tiered rollout strategy starting in 2026. While the company highlights robust technological integration and strong product interest, market participants are actively debating the impact of the launch pricing on near-term demand and the potential challenges of scaling production in a competitive EV landscape.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is currently experiencing high volatility as investors grapple with conflicting signals between geopolitical instability in the Middle East and a strengthening U.S. dollar, leading to intense debate over gold's historical role as a reliable safe-haven asset. Community sentiment is deeply divided, with many traders questioning the decoupling of gold from inflationary pressures while others view the current price action as a tactical shakeout for long-term accumulation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron shares are experiencing volatility despite posting blowout fiscal results and raising guidance, as investors weigh impressive AI-driven demand against the company's decision to significantly increase capital expenditures. While community sentiment remains polarized, many market participants are actively debating whether this pullback represents a classic 'sell the news' trap or a tactical buying opportunity fueled by long-term structural demand.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is currently under significant downward pressure as investors react to escalating geopolitical tensions in the Middle East, rising energy prices, and ongoing discussions regarding internal share sales and corporate governance. Market participants remain highly divided, with the community actively debating the company's financial viability, the potential impacts of the ongoing conflict on the broader economy, and allegations concerning the leadership's past associations.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is in focus as investors digest recent financial results and evaluate the company's ambitious revenue projections for 2026. The community is actively debating the impact of recent acquisitions, contract backlog quality, and the stock's significant short interest, with many weighing the long-term potential of lunar infrastructure projects against near-term execution and market volatility.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently drawing intense investor focus as the market weighs conflicting catalysts, including recent reports of an escalating federal safety probe into Full Self-Driving technology against positive sentiment driven by high-profile battery supply deals and robotaxi development. Community sentiment remains deeply divided, with bulls pointing to long-term autonomy and energy storage growth, while bears emphasize valuation concerns, production delays, and broader macro-economic pressures from rising energy costs.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is experiencing intense investor scrutiny as the stock faces downward pressure despite significant growth in its cloud and AI divisions, sparking heated community debate over whether it is a deep-value opportunity or a long-term trap. Investors are closely monitoring upcoming earnings and policy updates from China, with active discussions focused on whether the company's aggressive AI infrastructure spending will drive future profitability or continue to drag on near-term financials.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as investors grapple with heightened market volatility driven by escalating geopolitical tensions in the Middle East and concerns over persistent inflationary pressure. Community discourse is sharply divided between bears anticipating a deeper correction due to energy supply disruptions and bulls actively seeking buying opportunities during dips, reflecting broad anxiety over the potential impact of ongoing conflict on global supply chains and interest rate policy.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is facing significant downward pressure as market participants weigh geopolitical instability in the Middle East and concerns over potential stagflation against the company's recent strategic adjustments in China. While some investors remain focused on long-term value and share repurchases, the community is currently debating whether the stock is finding a floor or if it is poised for a deeper correction amid a broader market climate that favors capital preservation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NAGE It was asked on another forum whether Niagen Bio has any Phsse 2 trials beyond AT and Parkinson&#39;s disease.  What follows is an AI summary.  I have to do responses to this post to get them all mentioned. We know that the published peripheral artery disese trial had good results, and I have anecdotal evidence that peripheral neuropathy from chemotherapy is treatable with NR.  AI: Nicotinamide Riboside (NR), a precursor to the essential coenzyme NAD+, is currently being investigated in numerous Phase 2 clinical trials targeting a wide range of age-related and metabolic conditions.  
Neurological &amp; Neurodegenerative Disorders 
Parkinson’s Disease (NAD-PARK &amp; NR-SAFE): These Phase 2 trials investigated NR&#39;s neuroprotective potential, with doses up to 3000 mg daily showing a significant increase in brain NAD+ levels and improvements in clinical symptoms. 
Alzheimer’s Disease (N-DOSE AD): A dose-optimization trial (NCT05617508) is evaluating the effects of NR in patients with Alzheimer’s.

StockTwits Web

Niagen Bioscience Inc.

 It was asked on another forum whether Niagen Bio has any Phsse 2 trials beyond AT and Parkinson's disease.  What follows is an AI summary.  I have to do responses to this post to get them all mentioned. We know that the published peripheral artery disese trial had good results, and I have anecdotal evidence that peripheral neuropathy from chemotherapy is treatable with NR.  AI: Nicotinamide Riboside (NR), a precursor to the essential coenzyme NAD+, is currently being investigated in numerous Phase 2 clinical trials targeting a wide range of age-related and metabolic conditions.  
Neurological & Neurodegenerative Disorders 
Parkinson’s Disease (NAD-PARK & NR-SAFE): These Phase 2 trials investigated NR's neuroprotective potential, with doses up to 3000 mg daily showing a significant increase in brain NAD+ levels and improvements in clinical symptoms. 
Alzheimer’s Disease (N-DOSE AD): A dose-optimization trial (NCT05617508) is evaluating the effects of NR in patients with Alzheimer’s.

Jeff Gilligan

Huntington’s Disease (NAD-HD): A Phase 2 study (NCT06853743) conducted by Oslo University Hospital is examining the efficacy and safety of NR for this condition. 
Mild Cognitive Impairment (MCI): A completed Phase 2 trial (NCT02921659) tested 1 g/day of NR to assess its impact on cognition, cerebral blood flow, and brain volume. 
Ataxia-telangiectasia: A single-arm trial (NCT06324877) is testing NR&#39;s effect on ataxia scales and mitochondrial dysfunction in pediatric patients.  
ClinicalTrials.gov 
ClinicalTrials.gov 
 +7 
Cardiovascular &amp; Metabolic Health 
Peripheral Artery Disease (PAD): A randomized, double-blind study demonstrated that 1000 mg of NR daily significantly improved six-minute walking distance and functional mobility in PAD patients. 
Hypertension &amp; Arterial Stiffness: Ongoing trials (NCT03821623, NCT04040959) are exploring whether NR can lower systolic blood pressure and reduce vascular stiffness in middle-aged and older adults. 
 
 
ClinicalTrials.gov 
Show all

Clinicaltrials

ClinicalTrials.gov

Huntington’s Disease (NAD-HD): A Phase 2 study (NCT06853743) conducted by Oslo University Hospital is examining the efficacy and safety of NR for this condition. 
Mild Cognitive Impairment (MCI): A completed Phase 2 trial (NCT02921659) tested 1 g/day of NR to assess its impact on cognition, cerebral blood flow, and brain volume. 
Ataxia-telangiectasia: A single-arm trial (NCT06324877) is testing NR's effect on ataxia scales and mitochondrial dysfunction in pediatric patients.  


 
 +7 
Cardiovascular & Metabolic Health 
Peripheral Artery Disease (PAD): A randomized, double-blind study demonstrated that 1000 mg of NR daily significantly improved six-minute walking distance and functional mobility in PAD patients. 
Hypertension & Arterial Stiffness: Ongoing trials (NCT03821623, NCT04040959) are exploring whether NR can lower systolic blood pressure and reduce vascular stiffness in middle-aged and older adults. 
 
 


Heart Failure: A mechanistic study (NCT04528004) is evaluating NR&#39;s ability to improve myocardial mitochondrial function in patients undergoing heart surgery. 
Diabetic Neuropathy: A Phase 2 trial (NCT03685253) is investigating 1 gram of NR daily to treat small fiber neuropathy in patients with type 2 diabetes or impaired glucose tolerance.  
ClinicalTrials.gov 
ClinicalTrials.gov 
 +5 
Aging, Frailty &amp; Immunity 
Functional Decline in Aging (NADage): This trial (NCT06208527) aims to determine if 2000 mg of NR daily can improve clinical symptoms of frailty and cognitive function in the elderly. 
Systemic Lupus Erythematosus (SLE): A Phase 2 study (NCT06032923) sponsored by the National Heart, Lung, and Blood Institute is testing NR’s impact on immunometabolism and inflammation in SLE patients. 
Ulcerative Colitis: A pilot study (NCT05561738) is investigating NR&#39;s potential to restore mitochondrial function in pediatric patients with Ulcerative Colitis.

Heart Failure: A mechanistic study (NCT04528004) is evaluating NR's ability to improve myocardial mitochondrial function in patients undergoing heart surgery. 
Diabetic Neuropathy: A Phase 2 trial (NCT03685253) is investigating 1 gram of NR daily to treat small fiber neuropathy in patients with type 2 diabetes or impaired glucose tolerance.  


 
 +5 
Aging, Frailty & Immunity 
Functional Decline in Aging (NADage): This trial (NCT06208527) aims to determine if 2000 mg of NR daily can improve clinical symptoms of frailty and cognitive function in the elderly. 
Systemic Lupus Erythematosus (SLE): A Phase 2 study (NCT06032923) sponsored by the National Heart, Lung, and Blood Institute is testing NR’s impact on immunometabolism and inflammation in SLE patients. 
Ulcerative Colitis: A pilot study (NCT05561738) is investigating NR's potential to restore mitochondrial function in pediatric patients with Ulcerative Colitis.

Chemotherapy-Induced Peripheral Neuropathy: One study (NCT03642990) evaluated if the commercial NR supplement Niagen could prevent neuropathy in cancer patients receiving paclitaxel. 
IVF &amp; Fertility: A Phase 2 trial registered on the ANZCTR is exploring whether NR supplementation improves egg collection outcomes in women undergoing IVF.  
 
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With ... 
Dose will be via oral capsule supplementation at 25mg/kg/day divided into 3 doses (max 300mgs 3 times per day). Dosing will occur ... 
 
ClinicalTrials.gov 
A randomized placebo-controlled trial of nicotinamide riboside ... 
It is naturally found in milk and is available as a nutraceutical. Prior studies suggest that oral supplementation of NR is safe a...

Chemotherapy-Induced Peripheral Neuropathy: One study (NCT03642990) evaluated if the commercial NR supplement Niagen could prevent neuropathy in cancer patients receiving paclitaxel. 
IVF & Fertility: A Phase 2 trial registered on the ANZCTR is exploring whether NR supplementation improves egg collection outcomes in women undergoing IVF.  
 
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With ... 
Dose will be via oral capsule supplementation at 25mg/kg/day divided into 3 doses (max 300mgs 3 times per day). Dosing will occur ... 
 


 
A randomized placebo-controlled trial of nicotinamide riboside ... 
It is naturally found in milk and is available as a nutraceutical. Prior studies suggest that oral supplementation of NR is safe a...

@MattManzanita Thanks for this.  
My half-assed emotional take is that all are using oral dosing - it&#39;s ok but it is likely to only show trending results - nothing dramatic.  
The dose escalation studies I like but the duration is kinda short - anyway directionality with dose increase is always good data.  
The AD study is going all-in on data collection blood, csf, imaging, tissue. The investigators will have a valuable data set and I&#39;m hoping to see a good PR from it that may grab media attention. I think the Haukeland Park study is also collecting a lot of blood, tussue and imaging.  
Time will tell.  
As always not an expert just some guy&#39;s opinion.

 Thanks for this.  
My half-assed emotional take is that all are using oral dosing - it's ok but it is likely to only show trending results - nothing dramatic.  
The dose escalation studies I like but the duration is kinda short - anyway directionality with dose increase is always good data.  
The AD study is going all-in on data collection blood, csf, imaging, tissue. The investigators will have a valuable data set and I'm hoping to see a good PR from it that may grab media attention. I think the Haukeland Park study is also collecting a lot of blood, tussue and imaging.  
Time will tell.  
As always not an expert just some guy's opinion.